Clinical trialNCT07702578RecruitingPhase 3Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

SponsorTScan Therapeutics, Inc.Enrollment310AMLMDS

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Shrikanta Chattopadhyay, MD
TScan Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Health - Md Anderson Cancer Center
Gilbert, Arizona, United States
Yazan Samhouri, MD
Not, yet, recruiting
Honor Health Cancer Transplant Institute
Scottsdale, Arizona, United States
Abdullah Ladha, MD
Not, yet, recruiting
City of Hope
Duarte, California, United States
Monzr M Al Malki, MD
Recruiting
Stanford - School of Medicine
Stanford, California, United States
Hany Elmariah, MD
Not, yet, recruiting
University of Colorado - Anschutz Cancer Center
Aurora, Colorado, United States
Mathew Angelos, MD
Recruiting
Scri - Colorado Blood Cancer Institute
Denver, Colorado, United States
Marcello Rotta, MD
Recruiting
Yale
New Haven, Connecticut, United States
Lohith Gowda, MD
Recruiting
Memorial Cancer Institute
Hollywood, Florida, United States
Hugo Fernandez, MD
Recruiting
Moffitt Cancer Institute
Tampa, Florida, United States
Nelli Bejanyan, MD
Recruiting
Northside Hospital
Atlanta, Georgia, United States
Melholm Sohl, MD
Recruiting
University of Chicago
Chicago, Illinois, United States
Gregory Roloff, MD
Not, yet, recruiting
the University of Kansas Cancer Center
Kansas City, Kansas, United States
Rajat Bansal, MD
Not, yet, recruiting
Johns Hopkins University
Baltimore, Maryland, United States
Tania Jain, MD
Recruiting
Dana-Farber Cancer Institute - Hematology/oncology
Boston, Massachusetts, United States
Mahasweta Gooptu, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Yi-Bin Chen, MD
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Joseph Uberti, MD
Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, United States
Michele Donato, MD
Recruiting
Columbia University - Irving Medical Center
New York, New York, United States
Ran Reshef, MD
Recruiting
Mount Sinai Hospital
New York, New York, United States
Alla Keyzner, MD
Recruiting
the University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Anson Snow, MD
Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Saar Gill, MD, PhD
Recruiting
Sarah Cannon Research Institute - Tristar Bone Marrow Transplant (bmt)
Nashville, Tennessee, United States
Jeremy Pantin, MD
Recruiting
St. David'S South Austin Medical Center
Austin, Texas, United States
Uttam Rao, MD
Recruiting
Baylor University Medical Center
Dallas, Texas, United States
Luis Pineiro, MD
Recruiting
the University of Texas - Md Anderson Cancer Center
Houston, Texas, United States
Uday Popat, MD
Recruiting
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Sameem Abedin, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TSC-101

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Jun 2026
Primary completion: 30 Jun 2029
Completion: 30 Jun 2029
Last update posted: 22 Jul 2026
Registered enrollment: 310
Registry id: NCT07702578

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.